An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
Some places on Earth experience extreme cold that seems almost impossible to survive. In these…
For the first time since Independence, India is preparing to systematically measure household incomes and…
The Earth is a big and fascinating place, made up of large land areas called…
Reserve Bank of India has advanced its scheduled Open Market Operation (OMO) purchases. The central…
In a move reflecting India’s growing climate risks, the Reserve Bank of India has proposed…
Indian Railways has taken a major step towards smart and technology-driven railway stations. On January…